Navigation Links
Sangamo BioSciences Announces First Quarter 2013 Conference Call and Webcast
Date:5/1/2013

RICHMOND, Calif., May 1, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that the company will release its first quarter 2013 financial results on Wednesday, May 8, 2013, after the market closes. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review the financial results and discuss other business matters.

(Logo: http://photos.prnewswire.com/prnh/20130102/SF35903LOGO)

The conference call dial-in numbers are 877-377-7553 for domestic callers and 678-894-3968 for international callers. The passcode for the call is 52754725.  Participants may access the live webcast via a link on the Sangamo BioSciences website in the Investors section under "Events and Presentations" http://investor.sangamo.com/events.cfm. For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 8:00 p.m. ET on May 8, 2013 to 11:59 p.m. ET on May 15, 2013. The conference call replay numbers for domestic and international callers are 855-859-2056 and 404-537-3406, respectively. The conference ID number for the replay is 52754725.

About Sangamo

Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. It has ongoing Phase 2 and Phase 1/2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. Sangamo's other therapeutic programs are focused on monogenic diseases, including hemophilia and  hemoglobinopathies such as sickle cell anemia and beta-thalassemia, and a program in Parkinson's disease. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo has entered into a strategic collaboration with Shire to develop therapeutics for hemophilia and other monogenic diseases and has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at www.sangamo.com.

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sangamo BioSciences Announces Presentation At The Barclays Global Healthcare Conference
2. Sangamo BioSciences Announces Presentation At 33rd Annual Cowen And Company Health Care Conference
3. Sangamo BioSciences Reports Fourth Quarter And Full Year 2012 Financial Results
4. Sangamo BioSciences to Webcast Analyst Briefing on Thursday, December 6, 2012
5. Sangamo BioSciences Reports Second Quarter 2012 Financial Results
6. CytoVas And BD Biosciences Ink Alliance To Co-Develop Personalized Diagnostic For Vascular Health
7. Neurocrine Biosciences to Present at the Needham 12th Annual Healthcare Conference
8. Chipscreen Biosciences Announces Achievement of Primary Endpoint in Chidamide Registrational Trial in China
9. Ambit Biosciences Appoints David Parkinson, M.D., to Board of Directors
10. Cleave Biosciences Adds New Investor and $10 Million to Series A Financing
11. Neurocrine Biosciences Announces the Start of Phase IIb Study of Elagolix in Uterine Fibroids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... April 27, 2016 ... the  "Global Anesthesia Disposables Market 2016-2020"  report ... ) ,The global anesthesia disposables market ... of 4.03% during the period 2016-2020.  ... threat to patients, safety. Organizations like the ...
(Date:4/27/2016)... SAN FRANCISCO , April 27, 2016 /PRNewswire/ ...  is expected to reach USD 2.06 billion by ... View Research, Inc. Increasing consumer awareness towards a ... over the next seven years.      ... Improper diet intake coupled with rising health treatment ...
(Date:4/26/2016)... -- Hill-Rom Holdings, Inc. (NYSE: HRC ) invites ... Bank 41 st Annual Health Care Conference on Wednesday, ... are invited to listen to the live discussion via the ... at http://edge.media-server.com/m/p/mr4uxgas . A recorded replay of the discussion ... event and accessible at the links above until August 1, ...
Breaking Medicine Technology:
(Date:4/29/2016)... Toronto, ON (PRWEB) , ... April 29, 2016 ... ... GlutenFreeCoupons.ca and the Canadian Celiac Association (CCA), is pleased to announce the launch ... about gluten-free products, nutritional articles, recipes, and more. The purpose of the ...
(Date:4/29/2016)... ... ... For those who skip meals occasionally (which is pretty much everyone), two ... new lifestyle diet tips offered by nutritionists Pam Bonney and Priya Lawrence of Tried ... Bonny and Lawrence noted that because proper nutrition, including water, provides energy during the ...
(Date:4/29/2016)... ... 2016 , ... The infertility specialists at HRC Fertility/Orange County (HRC/OC) -- Dr. ... Potter -- are proud of the recent release of their 2014 in vitro fertilization ... published the latest verified data for 375 U.S. member clinics. *Preliminary data shows ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... for Duchenne muscular dystrophy, and funding for Duchenne research, participated in the April ... the Sarepta Therapeutic’s novel Duchenne drug eteplirsen. The meeting at the Marriott Conference ...
(Date:4/29/2016)... ... April 29, 2016 , ... Yisrayl Hawkins, Pastor and Overseer at ... of adding BC and AD, saying it is time to set the record straight. ... Yisrayl says this simply cannot possibly be true and offers explanation. , “To start ...
Breaking Medicine News(10 mins):